Tenaya Therapeutics (TNYA) FCF Margin (2026)
Tenaya Therapeutics (TNYA) posted FCF Margin of 323.33% for Q2 2026, up 96.12% on a QoQ basis from 8343.56% in Q1 2026.
Powered by 
Analysis
Tenaya Therapeutics (TNYA) FCF Margin (2026) Analysis & Trends
Tenaya Therapeutics has reported FCF Margin for 1 years, with the latest figure at 323.33% in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.36 Bn | 112.79 Mn | 59.74% |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | -826.50% |
| 3 | Iovance Biotherapeutics | 3.64 Bn | 3.35 Bn | 55.72 Mn | -66.71% |
| 4 | Legend Biotech | 3.54 Bn | 2.58 Bn | 251.50 Mn | -3.46% |
| 5 | uniQure | 2.98 Bn | 2.98 Bn | 5.49 Mn | -497.31% |
| 6 | Beam Therapeutics | 2.52 Bn | 2.52 Bn | - | -13,981.63% |
| 7 | Precigen | 2.38 Bn | 2.38 Bn | 52.17 Mn | -33.11% |
| 8 | Sarepta Therapeutics | 2.15 Bn | 1.35 Bn | 251.87 Mn | 48.98% |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 18.67% |
| 10 | Tenaya Therapeutics | 140.88 Mn | 140.88 Mn | - | -323.33% |